News & Events about Reata Pharmaceuticals Inc.
Globe Newswire
4 months ago
NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) breached their fiduciary duties to shareholders. The investigation concerns potential ...
Thinking about buying stock in Neximmune, ShiftPixy, IN8BIO, Relay Therapeutics, or Reata Pharmaceuticals? Thinking about buying stock in Neximmune, ShiftPixy, IN8BIO, Relay Therapeutics, or Reata Pharmaceuticals? PR Newswire NEW YORK, Sept. 8, 2022 NEW YORK, Sept. 8, 2022 /PRNewswire...
Reata Pharmaceuticals (NASDAQ:RETA Get Rating) had its price objective lifted by Citigroup from $43.00 to $46.00 in a report issued on Friday morning, The Fly reports. The firm currently has a buy rating on the stock. A number of other equities analysts have also weighed in on the company. StockNews...